Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 21, 2014; 20(3): 786-794
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.786
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.786
Figure 1 Kaplan-Meier survival curves of patients enrolled in this study.
Forty-four patients with hepatocellular carcinoma and established cirrhosis were enrolled and treated with sorafenib. A: Overall survival; B: Survival of patients stratified according to their baseline alpha-fetoprotein (AFP) levels (P = 0.021); C: Survival of patients stratified according to their baseline alkaline phosphatase (ALP) levels (P = 0.017).
- Citation: Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794
- URL: https://www.wjgnet.com/1007-9327/full/v20/i3/786.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i3.786